Vol.

No.

August 08, 2025Aug 08, 2025

DOWNLOAD THE PDF

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”

Cover Story

Free Podcast The Directors

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states

Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”

By Paul Goldberg

Mary Beckerle, a whitewater kayaker, has advice for all the folks in the cancer field: never catastrophize, never panic.

Free Guest Editorial

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death

By Angus (Gus) Reid

Free Guest Editorial

Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust

By Louis M. Weiner

Book Review Free

When public service ends abruptly, do books provide solace? An escape? Perspective?
Former NIH and FDA employees tell us what they are reading in 2025

By Sara Willa Ernst

Cancer Policy

ACOG says it will no longer accept federal funding

Trump administration broke law by canceling DEI research grants, GAO finds

HHS halts nearly $500M in mRNA-related vaccine contracts

Brown University reaches agreement with Trump administration to restore funding

All federal grants must be reviewed by Trump appointees, executive order directs

In Brief

Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program

Joseph Contessa appointed chair of radiation oncology at Rutgers Cancer Institute

Jaime LaMontagne named chief marketing officer of Astrin Biosciences

Clinical Roundup

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Drugs & Targets

FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

PREVIOUS ISSUE

CURRENT ISSUE

Recent Issues

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death

Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust

When public service ends abruptly, do books provide solace? An escape? Perspective?
Former NIH and FDA employees tell us what they are reading in 2025

Cancer Policy

ACOG says it will no longer accept federal funding

Trump administration broke law by canceling DEI research grants, GAO finds

HHS halts nearly $500M in mRNA-related vaccine contracts

Brown University reaches agreement with Trump administration to restore funding

All federal grants must be reviewed by Trump appointees, executive order directs

In Brief

Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program

Joseph Contessa appointed chair of radiation oncology at Rutgers Cancer Institute

Jaime LaMontagne named chief marketing officer of Astrin Biosciences

Clinical Roundup

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Drugs & Targets

FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login